BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 23481458)

  • 1. Attainment of goal and normalized lipid levels with lipid-modifying therapy in Malaysia.
    Hsu TY; Chirovsky D; Moy FM; Ambegaonkar BM
    Clin Ther; 2013 Apr; 35(4):450-60. PubMed ID: 23481458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attainment of normal lipid levels among patients on lipid-modifying therapy in Hong Kong.
    Ambegaonkar B; Chirovsky D; Tse HF; Lau YK; Tomlinson B; Li SK; Yue CS; Wong TH; Choi MC; Tunggal P; Sazonov V
    Adv Ther; 2012 May; 29(5):427-41. PubMed ID: 22562782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of lipid abnormalities and attainment of normal lipid levels among patients with dyslipidaemia: a pooled analysis of observational studies from five Asian countries.
    Unniachan S; Bash LD; Khovidhunkit W; Sri RZ; Vicaldo E; Recto C; Ambegaonkar BM
    Int J Clin Pract; 2014 Aug; 68(8):1010-9. PubMed ID: 24666791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs.
    Stacy TA; Egger A
    J Manag Care Pharm; 2006; 12(9):745-51. PubMed ID: 17249907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attainment of normal lipid levels among high cardiovascular risk patients: pooled analysis of observational studies from the United Kingdom, Sweden, Spain and Canada.
    Ambegaonkar BM; Bash LD; Chirovsky DR; Jameson K; Grant S; Nocea G; Pettersson B; Sazonov V
    Eur J Intern Med; 2013 Oct; 24(7):656-63. PubMed ID: 23953848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO.
    Nag SS; Daniel GW; Bullano MF; Kamal-Bahl S; Sajjan SG; Hu H; Alexander C
    J Manag Care Pharm; 2007 Oct; 13(8):652-63. PubMed ID: 17970603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?
    Sarawate CA; Cziraky MJ; Stanek EJ; Willey VJ; Corbelli JC; Charland SL
    Clin Ther; 2007 Jan; 29(1):196-209. PubMed ID: 17379061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of dyslipidemia and goal attainment after initiating lipid-modifying therapy: a Thai multicenter study.
    Khovidhunkit W; Silaruks S; Chaithiraphan V; Ongphiphadhanakul B; Sritara P; Nimitphong H; Benjanuwattra T; Ambegaonkar BM
    Angiology; 2012 Oct; 63(7):528-34. PubMed ID: 22222187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
    Roth EM; Rosenson RS; Jones PH; Davidson MH; Kelly MT; Setze CM; Lele A; Thakker K
    J Clin Lipidol; 2012; 6(6):534-44. PubMed ID: 23312049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
    Li JZ; Chen ML; Wang S; Dong J; Zeng P; Hou LW
    Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of mixed dyslipidemia among Australian patients undergoing lipid-modifying therapy.
    Colquhoun D; Chirovsky D; Sazonov V; Cui YA; Ambegaonkar B
    Exp Clin Cardiol; 2013; 18(1):e32-6. PubMed ID: 24294045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006.
    Tóth PP; Potter D; Ming EE
    J Clin Lipidol; 2012; 6(4):325-30. PubMed ID: 22836069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
    Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
    Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlates of repeat lipid testing in patients with coronary heart disease.
    Virani SS; Woodard LD; Wang D; Chitwood SS; Landrum CR; Urech TH; Pietz K; Chen GJ; Hertz B; Murawsky J; Ballantyne CM; Petersen LA
    JAMA Intern Med; 2013 Aug; 173(15):1439-44. PubMed ID: 23817669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid management in high risk coronary patients: how effective are we at secondary intervention?
    Zhu YY; Hayward PA; Hare DL; Stewart AG; Buxton BF
    Heart Lung Circ; 2012 Feb; 21(2):82-7. PubMed ID: 22153966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of lipid goal achievement in patients on extended-release nicotinic acid/laropiprant in primary care clinical practice.
    Dänschel W; Steinhagen-Thiessen E; Buffleben C; Pittrow D; Hildemann SK
    Curr Med Res Opin; 2013 Jan; 29(1):33-40. PubMed ID: 23157464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective review of sex differences in the management of dyslipidemia in coronary heart disease: an analysis of patient data from a Maryland-based health maintenance organization.
    Cooke CE; Hammerash WJ
    Clin Ther; 2006 Apr; 28(4):591-9. PubMed ID: 16750470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.